IKT News and Press, Inhibikase Therapeutics Inc. From 03/08/22

Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference...

Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones PR Newswire BOSTON and ATLANTA , Jan. 5, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics ...

Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals NRXP +48% after Zyesami increased likel...

Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease - Publication describes role of c-Abl and misfolded alpha-synuclein proteins in the initiation and pr...

Inhibikase Therapeutics (NASDAQ:IKT): Q3 GAAP EPS of -$0.18. Revenue of $0.33M (+725.0% Y/Y) Press Release For further details see: Inhibikase Therapeutics reports Q3 results

Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity PR Newswire BOSTON and ATLANTA , Nov. 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceut...

Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit PR Newswire ATLANTA and BOSTON , Oct. 27, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical compan...

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009 PR Newswire ATLANTA , Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical c...

Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease - Interim animal data indicate toxicology profile improves with extended daily oral d...

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy PR Newswire ATLANTA , Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "C...